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Abstract
Background: Residual alcohol effects on physiological and psychological symptoms are commonly experienced
the morning after alcohol consumption. The purpose of this study was to assess the effects of L-ornithine on
subjective feelings and salivary stress markers the morning after alcohol consumption and to investigate whether
L-ornithine acutely accelerates ethanol metabolism.
Methods: This study had a randomized, placebo-controlled, double-masked crossover design. Subjects were all healthy
Japanese adults with the ‘flusher’ phenotype for alcohol tolerance. In experiment 1, 11 subjects drank 0.4 g/kg body
weight alcohol 1.5 h before their usual bedtime. Half an hour after drinking, they ingested either a placebo or 400 mg
ornithine. The next morning on awakening, subjects completed a questionnaire containing a visual analog scale (VAS),
the Oguri-Shirakawa-Azumi sleep inventory MA version (OSA-MA), and a profile of mood states (POMS) and collected a
saliva sample for measurement of salivary stress markers (cortisol, secretory immunoglobulin A, and α-amylase). In
experiment 2, placebo or 400 mg ornithine were administrated to 16 subjects both before and after drinking, and the
feeling of drunkenness, breath ethanol concentration and one-leg standing time were repeatedly investigated until
180 min after alcohol consumption.
Results: There were significant decreases in “awareness”, “feeling of fatigue” and “lassitude” VAS scores and in
“anger-hostility” and “confusion” POMS scores and a significant increase in “sleep length” in the OSA-MA test. Salivary
cortisol concentrations on awakening were reduced after ornithine supplementation. There were no differences
between ornithine and placebo in any of the subjective or physiological parameters of acute alcohol metabolism.
Conclusions: Taking 400 mg ornithine after alcohol consumption improved various negative feelings and
decreased the salivary stress marker cortisol the next morning. These effects were not caused by an increase
in acute alcohol metabolism.
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Background
L-ornithine is an amino acid that is not incorporated in
proteins but functions in the urea cycle in the liver. The
urea cycle converts ammonia, a harmful nitrogen metab-
olite, into urea. Foods like corbiculidae clams, tuna, and
cheese contain high amounts of ornithine [1-3]. Admin-
istration of ornithine is well known to stimulate the urea
cycle [4,5]. In pharmacological therapy, ornithine is used
to decrease blood ammonia concentrations and reduce
the symptoms of hepatic encephalopathy associated with
liver cirrhosis [6]. In addition, ornithine improves the
subjective feeling of fatigue in patients with hepatic dis-
ease or evoked by exercise [7,8]. Alcohol consumption
transiently increases blood ammonia levels [9,10]. Both
ammonia and alcohol are toxic and mainly metabolized
in the liver, and there is some evidence that their re-
spective metabolisms influence each other [11]. Alcohol
dehydrogenase, which metabolizes ethanol to acetalde-
hyde, and aldehyde dehydrogenase (ALDH), which
metabolizes acetaldehyde to acetic acid, play pivotal
roles in degrading alcohol. The gene encoding ALDH2
is a major gene determining alcohol sensitivity and
drinking behavior, particularly in Asian people including
Japanese [12]. People who are heterozygous for wild-
type and mutated ALDH2 are classified as ‘flushers’.
Flushers have very weak ALDH2 activity and show rapid
flushing of the skin at comparatively low doses of alco-
hol owing to the accumulation of acetaldehyde in the
body. In contrast, non-flushers are homozygous for wild
type ALDH2 and have normal alcohol metabolism.
Although moderate use of alcohol has some beneficial
aspects, excessive consumption of alcohol is undoubtedly
harmful to the health. Alcohol also affects psychological
and physiological states. Relatively low consumption of
alcohol can shorten the initiation of sleep and promote
good moods such as conviviality or a general pleasant
feeling. Conversely, high consumption of alcohol in-
creases nocturnal awakening and may bring about bad
feelings, anxiety, or depression. Flushers in particular
tend to suffer from these negative effects due to their
low ability to metabolize alcohol. Thus, simple and
convenient methods for reducing the harmful effects
of alcohol will be beneficial.
We previously reported that 800 mg L-ornithine-L-
aspartate, a stable salt of L-ornithine and L-aspartic
acid, improves the feeling of fatigue in flushers, but not
in non-flushers, when waking up the morning after
drinking [13]. Although the study clearly showed the
effectiveness of L-ornithine-L-aspartate, the outcome
measures depended on subjective evaluations alone.
Furthermore, it remained unclear whether the observed
effects were predominantly caused by ornithine or by
aspartic acid, because L-ornithine-L-aspartate contains
equivalent amounts of ornithine and aspartic acid. In
the present study we performed two randomized, placebo-
controlled, double-masked cross over experiments using
flushers as subjects. In experiment 1, to objectively exam-
ine the effects of 400 mg ornithine on the negative effects
caused by alcohol consumption, we measured the typical
salivary stress markers cortisol, secretory immunoglobu-
lin A (sIgA), and α-amylase in addition to self-reported
subjective feelings the morning after drinking. Further-
more, we investigated both the subjective and physio-




Subjects were recruited voluntarily from employees of
Kirin Holdings to participate in the study. They were
healthy Japanese adults with ‘flusher’ type alcohol to-
lerability. The study population was composed of 10
males and 1 female in experiment 1 (age, 35.5 ± 2.4
years; body weight, 65.4 ± 3.6 kg), and 11 males and 5
females in experiment 2 (age, 33.7 ± 1.9 years; body
weight, 60.4 ± 2.7 kg). Subjects were free of medication
and had no medical history of serious illness, alcohol
abuse, or insomnia. All subjects signed an informed
consent form after sufficient explanation of the pur-
pose and design of this study. This study was approved
by the Kirin Holdings Ethics Committee and carried
out in accordance with the ethical principles of the
Declaration of Helsinki.
Alcohol patch test
Alcohol sensitivity was assessed using an alcohol patch
test kit (Life Care Giken, Toyama, Japan). The patch was
attached to the skin of the inner upper arm for 20 min
and then removed. Subjects whose skin showed ery-
thema in the patched area were judged to be flushers.
Questionnaires
A visual analog scale (VAS), the Oguri-Shirakawa-Azumi
sleep inventory MA version (OSA-MA), a profile of mood
states (POMS), and a drunkenness feeling test were used
in this study. The VAS used in this study was composed
of 7 questions regarding sleepiness, awareness, fatigue,
lassitude, sleeping contentment, deep sleep, and falling
asleep. In each of the questions subjects were instructed
to mark a spot on a 100 mm straight line according to
their feelings upon awakening (left end 0 = best, right end
100 =worst). The distance of the mark from the left end
was measured and used as the VAS score. A low VAS score
indicates a good mood.
The OSA-MA is a self-report questionnaire composed
of 16 items with a 4-point scale, which are consolidated
into “sleepiness on rising”, “initiation and maintenance
of sleep”, “frequent dreaming”, “refreshing”, and “sleep
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length” subscales [14]. A high OSA-MA subscale score
indicates better sleep state.
The POMS test (brief version) is composed of 30
questions with a 5-point scale about the current mood
state, which are classified into “tension-anxiety”,
“depression-dejection”, “anger-hostility”, “vigor”, “fatigue”,
and “confusion” subscales [15]. A low POMS score
indicates better mood state except for the “vigor” factor.
The drunkenness feeling test was designed to measure
subjective feelings of typical symptoms after alcohol
drinking. It was composed of 5 questions. With a 9-point
scale, regarding drunkenness, elation, swaying, weakness,
and discomfort.
Saliva collection and measures
Saliva samples were collected by using cotton swabs in
Salivette devices (Salimetrics, State College, PA). Subjects
were instructed to refrigerate sample tubes after collection
and submit them to the laboratory on the morning of the
study day. Sample tubes were immediately centrifuged at
1,500 × g for 10 min to collect the saliva from the swab.
Saliva samples were stored at −80C until analysis. Corti-
sol, sIgA and α-amylase concentrations were determined
by assay kits according to the manufacturer’s instructions
(Salimetrics).
Breath collection and measures
Subjects exhaled completely into TedlarW gas sampling
bags (As One, Tokyo, Japan). Ethanol concentrations of
the breath samples were immediately assessed by etha-
nol detector tubes (Gastec, Kanagawa, Japan).
One-leg standing time
Subjects were instructed to stand on one leg with their
eyes closed, with the contralateral knee flexed slightly
and the hands placed at the waist. Time before falling
over was measured and the average time of 3 repetitions
was determined.
Experimental design
The study consisted of two randomized, placebo-
controlled, double-masked crossover experiments. Sub-
jects were asked to take capsules containing ornithine
or placebo during each experiment. The order of sup-
plements was randomly determined for each subject and
kept secret by the independent party until the data valid-
ation was completed, so that both subjects and inves-
tigators involved in the experiment were unaware of each
subject’s assignment. The placebo capsules contained
microcrystalline cellulose (Asahi Kasei Chemicals, Tokyo,
Japan), and the ornithine capsules contained 500 mg
L-ornithine monohydrochloride (Kyowa Wellness, Tokyo,
Japan), which contains 400 mg ornithine. The two types of
capsule were identical in appearance. Subjects were
allowed free access to water, except during a water
fasting period, but were instructed to take similar a-
mounts of water between the trials. To eliminate the
effects of the test supplements and alcohol consumed
in the first trial, the second trial was performed no
less than 2 days later.
Experiment 1 was done in subjects’ homes. Subjects all
ate the same dinner 3.5 h before their usual bed time and
then rested for 2 h with no food and drink. Subjects took a
saliva sample and then drank 0.4 g/kg body weight of alco-
hol served as beer (5% alcohol) over 0.5 h. Subjects took
the capsules containing placebo or ornithine 0.5 h after
drinking and went to bed after another 0.5 h. The next
morning, saliva collection and questionnaires (VAS, OSA-
MA and POMS) were completed just after awakening.
Experiment 2 was done in the laboratory for a max-
imum of 5 subjects in one day. Subjects fasted for 2 h
from 3 pm, and then took the capsules. After taking the
capsules, the subjects drank alcohol as in experiment 1.
Subjects took the same capsules again 0.5 h after drinking
and then rested for 2.5 h. They repeated the drunkenness
feeling test, breath collection and one foot standing test
before drinking and 0, 30, 60, 120 and 180 min after
drinking.
Statistical analysis
Data are expressed as mean ± SEM. The questionnaire
scores of VAS, OSA-MA, and POMS and salivary stress
markers were compared using two tailed parametric
paired t-tests. Other parameters were compared using
two-way analysis of variance for repeated measures. A
p-value of < 0.05 was considered statistically significant.
Results
In experiment 1, sleep duration did not significantly dif-
fer between placebo and ornithine study days (6.2 ± 0.3
and 6.1 ± 0.3 h, respectively), as subjects were asked to
keep their usual daily rhythm. Mean VAS and POMS
scores (except for “vigor”) were lower and OSA-MA and
“vigor” POMS scores were higher after ornithine supple-
mentation than after placebo. These changes indicate that
ornithine supplementation resulted in a better subjective
mood, with significant improvements in VAS scores for
“awareness”, “feeling of fatigue”, and “lassitude”, the OSA-
MA scores for “sleep length”, and the POMS scores for
“anger-hostility” and “confusion” (Table 1).
In addition to the subjective feelings, salivary cortisol at
the time of awakening was significantly decreased by orni-
thine administration (Figure 1). There were no significant
changes in salivary sIgA or amylase concentrations.
To evaluate the effects of ornithine on acute ethanol
metabolism, we investigated the effects of ethanol in-
take on the subjective feeling of drunkenness, on breath
ethanol concentrations and on one-leg standing time in
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experiment 2. Intake of ethanol clearly affected both
subjective and physiological states immediately after
drinking. There were no significant differences between
placebo and ornithine in any of the parameters (Table 2).
Discussion
We evaluated the effects of ornithine on the alcohol-
induced deterioration of mood states and on salivary
stress markers the morning after alcohol intake in
experiment 1 and on acute ethanol metabolism in ex-
periment 2. Although flushers only constitute approxi-
mately 35% of the Japanese population [16,17], we chose
to only use flushers as our study subjects. In a previous
study we showed that ornithine-aspartate supplementa-
tion ameliorated alcohol-derived feelings of fatigue in
flushers but not in non-flushers using almost the same
study design as in the present study [13]. To be able to
observe the effects of ethanol to the same degree, we
decided to only screen flushers in this study. Previous
studies by other groups generally used larger amounts of
alcohol (0.7 to 1.6 g/kg body weight) [18-20], but the
amount of alcohol consumed by flushers in our previ-
ous study (0.4 g/kg body weight) was considered ap-
propriate to evoke the negative effects of alcohol the
next morning.
In experiment 1, the subjective VAS factors “aware-
ness”, “feeling of fatigue”, and “lassitude”, the OSA-MA
factor “sleep length”, and the POMS factors “anger-
hostility” and “confusion” the morning after drinking
were significantly improved by ornithine intake. As all
subjective factors tended to be improved by ornithine in-
take; alcohol-derived negative feelings seemed to be
improved. Considering the fact that the OSA-MA factor
“sleep length” was improved but substantive sleep time
was not, ornithine made the subjects feel subjectively
that they slept longer, even though the actual duration
was the same.
Furthermore, the salivary stress marker cortisol was
significantly reduced by ornithine intake. These results
suggest that taking 400 mg of ornithine after alcohol con-
sumption improves the mood on awakening, which is
confirmed by the decrease in an objective stress marker.
In experiment 2 we aimed to clarify the influence of
ornithine on acute alcohol metabolism. The feeling of
drunkenness and other subjective and physiological
symptoms of alcohol consumption were not significantly
Table 1 The effects of ornithine or placebo on VAS,
OSA-MA, and POMS scores the morning after alcohol
consumption (experiment 1)
Placebo Ornithine
VAS Sleepiness 52.1 ± 5.1 38.6 ± 5.6
Awareness 46.5 ± 5.7 32.6 ± 3.5*
Feeling of fatigue 44.2 ± 4.8 30.1 ± 4.3*
Lassitude 48.2 ± 5.4 35.7 ± 5.1*
Sleeping contentment 40.8 ± 6.1 35.0 ± 5.6
Deep sleep 40.0 ± 5.3 32.0 ± 5.3
Falling asleep 34.3 ± 6.5 31.4 ± 6.0
OSA-MA Sleepiness on rising 41.3 ± 2.0 44.0 ± 1.6
Initiation and maintenance of sleep 45.4 ± 3.2 48.8 ± 1.9
Frequent dreaming 48.1 ± 2.5 52.9 ± 2.1
Refreshing 47.0 ± 2.1 49.7 ± 1.3
Sleep length 38.0 ± 2.2 44.0 ± 2.3*
POMS Tension-Anxiety 41.2 ± 2.6 38.4 ± 2.2
Depression-Dejection 44.4 ± 2.4 43.5 ± 2.1
Anger-Hostility 41.6 ± 1.0 39.5 ± 1.5*
Vigor 39.3 ± 2.4 44.9 ± 2.2
Fatigue 46.3 ± 2.9 41.2 ± 1.3
Confusion 55.0 ± 2.9 47.8 ± 1.5*
















































Figure 1 Salivary concentrations of (A) cortisol, (B) sIgA, and (C) α-amylase before drinking and after awakening. Open bars indicate
control and closed indicate ornithine. Values are mean ± SEM, *p < 0.05.
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altered by ornithine intake. Thus, ornithine has little in-
fluence on acute alcohol metabolism at this dosage and
the effect of ornithine on the alcohol-derived mood state
the next morning was not caused by increased alcohol
metabolism. Ornithine must therefore affect mood and
physical state the next morning through other me-
chanisms. One of the possibilities may be through am-
monia metabolism. Ammonia metabolism is disturbed by
alcohol consumption [10], but is stimulated by ornithine
administration [5,6]. Furthermore, there is a correlation
between decreased ammonia metabolism and fatigue
[21,22]. Thus, we speculate that ornithine may improve
subjective feelings like “feeling of fatigue” by correcting
the imbalance in ammonia metabolism caused by alcohol
consumption. Further extensive studies are needed to
clarify these associations.
Another mechanism behind the effects of ornithine on
mood states after alcohol consumption may be through
the improvement in sleep quality. Low amounts of alcohol
can aid falling asleep, whereas higher amounts of alcohol
cause sleep disturbances including frequent awakening
and impaired normal sleep patterns. Omori et al. reported
that oral administration of ornithine increased the amount
of non-rapid eye movement (NREM) sleep in mice with-
out changing the amount of rapid eye movement (REM)
sleep [23]. In addition, intracerebroventricular injection of
ornithine has a sedative effect on neonatal chicks, and or-
nithine can serve as a precursor for glutamate and proline,
which have also been reported to have sedative or hyp-
notic effects [24-26]. Thus, the effect of ornithine on sleep
length may be partially mediated by improvements in the
disturbed sleep patterns caused by alcohol consumption.
Along with the subjective parameters, ornithine also
improved salivary concentrations of cortisol. Cortisol is
used in many studies as an indicator of the stress re-
sponse of the hypothalamic-pituitary-adrenal (HPA)
axis [27-30], which is activated by exposure to an
acute stressor. A previous report has shown that oral
administration of ornithine in mice reduced the stress-
induced corticosterone levels [31]. Thus, ornithine may
improve stress on awakening through suppression of
the HPA axis.
There were some limitations with respect to the analysis,
which may affect the accuracy of the results. The sample
size was not sufficient to lead to a firm conclusion (experi-
ment 1; n = 11, experiment 2; n = 16), and the proportion
of female subjects was notably low in experiment 1. More
extensive studies are needed to confirm our findings.
We investigated the effects of ornithine on the
alcohol-derived adverse effects on subjective feelings and
salivary markers the morning after alcohol consumption
and on acute alcohol metabolism. Ornithine improved
various negative feelings and decreased the salivary
stress marker cortisol, but did not affect acute alcohol
metabolism. Our results show that intake of 400 mg or-
nithine after alcohol consumption improved feelings of
stress and fatigue upon awakening the next morning.
Ornithine may be a potential dietary supplement for at-
tenuating the morning after adverse psychological and
physiological effects of alcohol.
Table 2 Breath alcohol content, one-leg standing time, and drunkenness feeling test scores before and after drinking
alcohol (experiment 2)
Before Time after drinking (min)
Condition drinking 0 30 60 120 180
Breath alcohol content Placebo 0.0 ± 0.0 458.3 ± 60.9 320.9 ± 36.2 217.2 ± 18.0 106.3 ± 11.0 48.8 ± 6.0
(ppm) Ornithine 0.0 ± 0.0 437.7 ± 53.8 290.9 ± 25.0 216.0 ± 14.9 103.8 ± 9.5 45.3 ± 5.1
One-leg standing time Placebo 40.6 ± 4.3 25.3 ± 4.7 25.0 ± 3.8 29.8 ± 4.6 34.5 ± 4.7 40.4 ± 5.0
(s) Ornithine 41.5 ± 5.2 27.3 ± 3.9 23.2 ± 4.4 24.1 ± 3.9 32.3 ± 4.4 37.4 ± 4.6
Drunkenness feeling test
Drunkenness Placebo 1.0 ± 0.0 7.8 ± 0.3 5.8 ± 0.6 5.2 ± 0.5 4.1 ± 0.5 2.8 ± 0.3
Ornithine 1.0 ± 0.0 7.4 ± 0.3 6.3 ± 0.5 4.9 ± 0.5 4.4 ± 0.5 3.3 ± 0.5
Elation Placebo 1.8 ± 0.4 7.1 ± 0.4 5.5 ± 0.5 4.8 ± 0.5 3.9 ± 0.5 2.8 ± 0.5
Ornithine 1.9 ± 0.3 6.8 ± 0.4 5.6 ± 0.4 5.1 ± 0.5 4.3 ± 0.5 3.1 ± 0.5
Swaying Placebo 1.1 ± 0.1 5.3 ± 0.6 3.8 ± 0.7 3.0 ± 0.6 2.4 ± 0.4 2.0 ± 0.4
Ornithine 1.0 ± 0.0 5.1 ± 0.6 3.4 ± 0.6 3.2 ± 0.6 2.5 ± 0.5 2.5 ± 0.5
Weakness Placebo 1.8 ± 0.4 3.3 ± 0.7 3.6 ± 0.6 3.4 ± 0.6 2.8 ± 0.5 2.1 ± 0.4
Ornithine 1.7 ± 0.3 3.5 ± 0.6 3.4 ± 0.8 3.3 ± 0.6 2.8 ± 0.5 2.2 ± 0.5
Discomfort Placebo 1.4 ± 0.3 1.5 ± 0.3 1.5 ± 0.3 1.6 ± 0.2 2.1 ± 0.4 1.7 ± 0.3
Ornithine 1.1 ± 0.1 1.8 ± 0.4 1.4 ± 0.3 1.4 ± 0.3 1.8 ± 0.4 1.4 ± 0.1
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